Antileishmanial Activity of the Antiulcer Agent Omeprazole

doi:10.1128/AAC.46.8.2569-2574.2002

Paper

Antileishmanial Activity of the Antiulcer Agent Omeprazole

Published Aug 1, 2002 · Suping Jiang, J. Meadows, S. A. Anderson

Antimicrobial Agents and Chemotherapy

Q1 SJR score

45

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

ABSTRACT The benzimidazole compound omeprazole, used widely for the treatment of peptic ulcer disease, inhibits the growth of Leishmania donovani, the causative agent of visceral leishmaniasis. Promastigotes cultured at acidic pH and amastigotes within infected macrophages are reduced 90% or more with 150 μM omeprazole. Antiparasitic action of the drug is due to its inhibition of the P-type K+,H+-ATPase on the surface membrane. This enzyme is important for pH homeostasis and the maintenance of proton motive force across the membrane in Leishmania. The drug is effective only at acidic pH, a condition that mimics the in vivo environment within the phagolysosomal vesicles where the amastigote form of the parasite resides. Omeprazole deserves consideration as an alternative to currently available chemotherapeutics, which have severe toxic side effects.

Study Snapshot

Omeprazole, a common antiulcer drug, effectively inhibits Leishmania donovani growth at acidic pH, offering a potential alternative to toxic chemotherapeutics.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Antileishmanial Activity of the Antiulcer Agent Omeprazole

Sign up to use Study Snapshot

References

Citations

Repurposing of rabeprazole as an anti-Trypanosoma cruzi drug that targets cellular triosephosphate isomerase

Rabeprazole shows promise as an effective anti-Trypanosoma cruzi drug, 14.5 times more effective than benznidazole, by targeting cellular triosephosphate isomerase.

Therapeutic efficacy of proton pump inhibitor (omeprazole) on cryptosporidiosis parvum in immunosuppressed experimental mice

Omeprazole shows potential as a novel treatment for cryptosporidiosis parvum, with better results than nitazoxanide when combined with it.

Integration of metabolomics and transcriptomics revealed the biosynthetic mechanism of anti-parasitic compounds in Salinivibrio proteolyticus strain YCSC6

Metabolomics and transcriptomics reveal the biosynthetic mechanism of anti-parasitic compounds in Salinivibrio proteolyticus strain YCSC6, aiding in the exploitation of more anti-parasitic agents for aquaculture.

P-type transport ATPases in Leishmania and Trypanosoma

P-type ATPases play a crucial role in maintaining cellular ion homeostasis and membrane lipid asymmetry in human pathogenic trypanosomatids, aiding in growth, adaptation, infectivity, and survival.

Omeprazole as an Adjuvant to Praziquantel in Treatment of Experimental Schistosomiasis Mansoni

Omeprazole combined with praziquantel shows a synergistic effect in reducing juvenile worm counts and liver egg loads in Schistosoma mansoni-infected mice.